<DOC>
	<DOCNO>NCT00503529</DOCNO>
	<brief_summary>The purpose study ass : - TBE antibody persistence 24 , 34 , 46 58 month ( applicable ) first booster TBE vaccination FSME-IMMUN 0.5ml give Study 223 , mean ELISA ( IMMUNOZYM FSME IgG ) Neutralization test ( NT ) , - TBE antibody response second booster vaccination FSME-IMMUN 0.5ml present study , mean ELISA NT , - Safety FSME-IMMUN 0.5ml second booster vaccination .</brief_summary>
	<brief_title>TBE Antibody Persistence Booster Vaccination Study Adults ( Follow-up Study 223 )</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Tick-Borne</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects participate Study 223 eligible participation study : understand nature study , agree provision provide write informed consent receive first booster vaccination FSMEIMMUN 0.5ml course study 223 blood drawn first booster vaccination Study 223 . Subjects exclude participation study : receive TBE vaccination since first booster vaccination FSMEIMMUN 0.5ml history infection vaccination flavivirus ( e.g . dengue fever , yellow fever , Japanese Bencephalitis ) since first booster vaccination FSMEIMMUN 0.5ml know HIV positive ( special HIV test require purpose study ) since first booster vaccination FSMEIMMUN 0.5ml know suspect problem drug alcohol abuse ( &gt; 4 liter wine / week equivalent level alcoholic beverage ) . Subjects eligible booster vaccination : clinically healthy , ( i. e. physician would reservations vaccinate FSMEIMMUN 0.5ml outside scope clinical trial ) suffer disease ( e.g . autoimmune disease ) undergo form treatment ( e.g . systemic corticosteroid ) expect influence immunological function female childbearing potential pregnant breastfeeding booster vaccination ( positive pregnancy test result medical examination booster vaccination ) show allergic reaction one component vaccine since first booster vaccination Study 223 simultaneously participate another clinical trial include administration investigational product within six week prior booster vaccination end study agree keep Subject Diary . Subjects meet eligibility criterion , febrile illness ( body temperature &gt; = 38.0Â°C , measure orally ) schedule time vaccination , vaccinate body temperature return normal . Subjects administer vaccination within 2 week prior booster vaccination vaccinate interval two week pass . If subject receive antipyretic within 4 hour prior schedule time vaccination , vaccination perform late time . If subject tickbite within 4 week schedule booster vaccination , vaccination shall delay interval 4 week pass since tickbite order avoid interference diagnostic assay event TBE infection . If subject donate blood plasma receive blood transfusion immunoglobulin within 4 week schedule booster vaccination , vaccination shall delay interval 4 week pass .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>